What is ReliantHeart?
ReliantHeart Inc. is at the forefront of developing mechanical circulatory support therapies for patients suffering from advanced stage heart failure. The company's flagship product, the HeartAssist5®, is a next-generation ventricular assist device (VAD) that has received CE Mark approval for commercial distribution in Europe. This implantable, electric pump is engineered to provide ventricular support for individuals with end-stage heart failure. Notably, the HeartAssist5® stands as the world's only remotely monitored VAD, offering advanced patient care capabilities.
How much funding has ReliantHeart raised?
ReliantHeart has raised a total of $5.5M across 3 funding rounds:
Private Equity
$3.9M
Debt
$1.5M
Debt
$150K
Private Equity (2015): $3.9M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in ReliantHeart
PPP
Public-Private Partnership
What's next for ReliantHeart?
The recent major strategic investment positions ReliantHeart for accelerated growth and market expansion. With its CE Mark approval for the HeartAssist5® in Europe, the company is poised to scale its operations and further penetrate the advanced heart failure market. Future strategic initiatives will likely focus on enhancing its remote monitoring technology, expanding clinical applications, and potentially pursuing further regulatory approvals in other key global markets. This infusion of capital is expected to fuel research and development, bolster manufacturing capabilities, and strengthen its commercialization efforts, solidifying its role as a leader in life-saving cardiac support.
See full ReliantHeart company page
